Kian-Huat Lim, MD, PhD

Medical Oncologist

Kian-Huat Lim

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Video thumbnail for Kian-Huat Lim, MD, PhD

Watch video on YouTube

Kian-Huat Lim, MD, PhD

4 mins

Kian-Huat Lim, MD, PhD, Washington University medical oncologist at Siteman Cancer Center, discusses how receiving care at Siteman makes more treatment options available for patients.

Clinical Expertise

  • Gastrointestinal oncology, colorectal cancer, pancreatic cancer, hepatobiliary cancer, novel therapeutics, clinical trials

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Medical Oncology, WashU Medicine

Board Certification

  • 2011: American Board of Internal Medicine

Training

  • 1998 - 1999: Intern, National Taiwan University Hospital, Taipei, Taiwan
  • 1999 - 2002: Resident, Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • 2007 - 2009: Resident, Internal Medicine, Washington University, St. Louis, MO
  • 2009 - 2010: Fellow, Hematology and Oncology, Washington University, St. Louis, MO
  • 2010 - 2013: Fellow, Medical Oncology, National Cancer Institute, National Health Institute, Bethesda, MD

Education

  • 1999: MD, National Taiwan University College of Medicine, Taipei, Taiwan
  • 2006: PhD, Molecular Cancer Biology Program, Duke University, Durham, NC

Research & Selected Publications

Research Interest

Understanding the signaling interplay between the inflammatory and oncogenic pathways, how they affect tumor initiation, progression and response to treatments, and translating these findings into novel treatments for patients. Clinical interest in gastrointestinal such as colorectal, pancreatic and hepatobiliary cancers.

Research Publications

Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic
Authors:

Somani VK, Zhang X, Chen TH, one or more additional authors omitted Lim KH

Journal & Year:

Mol Cancer | 2026

Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade
Authors:

Bansod SP, Chen TH, Somani VK, one or more additional authors omitted Lim KH

Journal & Year:

bioRxiv | 2025

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Authors:

Grierson PM, Wolf C, Suresh R, one or more additional authors omitted Lim KH

Journal & Year:

Clin Cancer Res | 2025

Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy
Authors:

Liu X, Baer JM, Stone ML, one or more additional authors omitted Lim KH, one or more additional authors omitted DeNardo DG

Journal & Year:

Sci Transl Med | 2024

The TRIM4 E3 ubiquitin ligase degrades TPL2 and is modulated by oncogenic KRAS
Authors:

Bansod S, Dodhiawala PB, Geng Y, one or more additional authors omitted Lim KH

Journal & Year:

Cell Rep | 2024

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Authors:

Klomp JA, Klomp JE, Stalnecker CA, one or more additional authors omitted Lim KH, one or more additional authors omitted Der CJ

Journal & Year:

Science | 2024

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer
Authors:

Bulle A, Liu P, Seehra K, one or more additional authors omitted Lim KH

Journal & Year:

Nat Commun | 2024

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
Authors:

Wu Y, Chen S, Yang X, one or more additional authors omitted Lim KH, one or more additional authors omitted Chen F

Journal & Year:

Cancer Res | 2023